<DOC>
	<DOCNO>NCT00302341</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority pafuramidine maleate ( DB289 ) versus trimethoprim-sulfamethoxazole ( TMP-SMX ) treatment mild moderately severe Pneumocystis pneumonia ( PCP ) .</brief_summary>
	<brief_title>DB289 Versus TMP-SMX Treatment Acute Pneumocystis Jiroveci Pneumonia ( PCP )</brief_title>
	<detailed_description>The gold standard treatment PCP trimethoprim-sulfamethoxazole ( TMP-SMX ) . This drug highly effective ; however , significant number patient unable complete course therapy due adverse event , life-threatening . In addition , mutation confer resistance sulfa-based drug microorganisms increasingly report P. jiroveci . A potential role mutation confer clinical resistance PCP breakthroughs prophylaxis regimen base sulfa drug actively study . Second third line agent combination PCP treatment also limit efficacy and/or adverse event . A new agent pafuramidine maleate ( DB289 ) , well document activity P. carinii animal model , document efficacy preliminary study trial HIV-infected patient PCP intolerant resistant TMP-SMX , well tolerate trial demonstrate low toxicity profile Phase 1 study , would meet significant medical need . Furthermore , pafuramidine maleate active pathogen responsible significant morbidity mortality patient AIDS develop world , like different strain Plasmodium ( malaria ) Cryptosporidium parvum . The decrease rate PCP country patient AIDS access HAART present significant challenge completion development program . The last published trial PCP treatment conduct ACTG 24 U.S. site May 1991 june 1993 . That study need decrease plan sample size 195 due low enrollment . This represent important challenge program .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Documented presumptive HIV infection Signs symptom PCP present least 5 day Pneumocystis jiroveci confirm BAL fluid induce sputum sample Suitable candidate oral therapy Alveolararterial oxygen ( Aa ) gradient &lt; = 45 mm Hg room air partial pressure oxygen ( pO2 ) &gt; = 60 mm Hg No 48 hour prior treatment precede 7 day PCP treatment full dos ; failure Pneumocystis prophylaxis use medication recommend treatment PCP dose less recommended CDC Guidelines acceptable . Unwilling unable discontinue use medication antiPCP activity AIDS relate cachexia ( weight loss 10 % ideal body weight ) Severe diarrhea and/or vomit History hypersensitivity severe life threaten toxicity TMPSMX , sulfonamides pentamidine Active illicit drug use Impending respiratory failure need intubation AST ALT level &gt; 3 time upper limit normal History pancreatitis Severe PCP Karnofsky score &lt; = 20 Terminal HIV disease life expectancy le 6 month Acute concurrent pulmonary pathological condition would obscure evaluation response therapy Concomitant use amphotericin B , gangciclovir , cyclosporine , warfarin , thiazide diuretic , phenytoin , methotrexate , leucovorin Receipt systemic corticosteroid ( except replacement therapy ) within 14 day study entry high dos 3 consecutive day . Concomitant use corticosteroid , replacement dos adrenal insufficiency , also exclude unless patient meet CDC criterion use corticosteroid treatment PCP Pregnant lactate woman The subject previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Pulmonary disease</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>Hypoxemia</keyword>
	<keyword>AIDS</keyword>
	<keyword>Pneumocystis jiroveci</keyword>
</DOC>